

Richard Schulz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4811092/richard-schulz-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188
papers

11,458
citations

51
h-index

105
g-index

197
ext. papers

12,215
ext. citations

5.7
avg, IF

6.07
L-index

#	Paper	IF	Citations
188	Matrix metalloproteinase-2 mediates ribosomal RNA transcription by cleaving nucleolar histones. <i>FEBS Journal</i> , 2021 , 288, 6736-6751	5.7	1
187	MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling. <i>Cardiovascular Research</i> , 2021 , 117, 188-200	9.9	22
186	Multifunctional intracellular matrix metalloproteinases: implications in disease. <i>FEBS Journal</i> , 2021 ,	5.7	33
185	Letter by Hwang et al Regarding Article, "Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans". <i>Circulation</i> , 2021 , 144, e166-e167	16.7	1
184	MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin. <i>Biochemical Pharmacology</i> , 2021 , 193, 114744	6	4
183	Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury. <i>Cardiovascular Research</i> , 2020 , 116, 1021-1031	9.9	7
182	Predictive Value of Matrix Metalloproteinases and Their Inhibitors for Mortality in Septic Patients: A Cohort Study. <i>Journal of Intensive Care Medicine</i> , 2020 , 35, 95-103	3.3	5
181	Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury. <i>Basic Research in Cardiology</i> , 2019 , 114, 42	11.8	14
180	Prognostic Value of MMP-9 -1562 C/T Gene Polymorphism in Patients With Sepsis. <i>Biomarker Insights</i> , 2019 , 14, 1177271919847951	3.5	4
179	Structure and proteolytic susceptibility of the inhibitory C-terminal tail of cardiac troponin I. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019 , 1863, 661-671	4	5
178	Matrix metalloproteinase (MMP)-2 activation by oxidative stress decreases aortic calponin-1 levels during hypertrophic remodeling in early hypertension. <i>Vascular Pharmacology</i> , 2019 , 116, 36-44	5.9	13
177	Matrix Metalloproteinase-2 2018 , 2996-3005		
176	Nucleolar Matrix Metalloproteinase-2 Regulates rRNA Transcription. <i>FASEB Journal</i> , 2018 , 32, lb416	0.9	
175	Matrix Metalloproteinase Inhibitors Attenuate Doxorubicin-Induced Heart Failure by Preventing Cardiac Titin Proteolysis. <i>FASEB Journal</i> , 2018 , 32, 864.10	0.9	
174	Proteolytic Digestion of Serum Cardiac Troponin I as Marker of Ischemic Severity. <i>journal of applied laboratory medicine, The</i> , 2018 , 3, 450-455	2	12
173	Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018 , 96, 1238-1245	2.4	5
172	High fat diet modulates inflammatory parameters in the heart and liver during acute <i>Trypanosoma cruzi</i> infection. <i>International Immunopharmacology</i> , 2018 , 64, 192-200	5.8	5

171	TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: Multivariate model. <i>PLoS ONE</i> , 2017 , 12, e0171191	3.7	14
170	Doxycycline and Benznidazole Reduce the Profile of Th1, Th2, and Th17 Chemokines and Chemokine Receptors in Cardiac Tissue from Chronic -Infected Dogs. <i>Mediators of Inflammation</i> , 2016 , 2016, 3694714	4.3	9
169	Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016 , 311, H183-9	5.2	14
168	Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 94, 153-161	5.8	23
167	Doxycycline attenuates renal injury in a swine model of neonatal hypoxia-reoxygenation. <i>Shock</i> , 2015 , 43, 99-105	3.4	12
166	Morus nigra leaf extract improves glycemic response and redox profile in the liver of diabetic rats. <i>Food and Function</i> , 2015 , 6, 3490-9	6.1	24
165	Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial. <i>International Journal of Cardiology</i> , 2015 , 197, 147-53	3.2	20
164	Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats. <i>European Journal of Pharmacology</i> , 2015 , 765, 164-70	5.3	11
163	ISDN2014_0147: The use of broccoli sprouts as a neuropreventative agent in a neonatal rat model of the fetal inflammatory response. <i>International Journal of Developmental Neuroscience</i> , 2015 , 47, 43-43 ²⁻⁷	3.7	7
162	Immunomodulation by lipid emulsions in pulmonary inflammation: a randomized controlled trial. <i>Critical Care</i> , 2015 , 19, 226	10.8	28
161	Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. <i>MethodsX</i> , 2015 , 2, 440-5	1.9	89
160	Dynamic Alterations to β Actinin Accompanying Sarcomere Disassembly and Reassembly during Cardiomyocyte Mitosis. <i>PLoS ONE</i> , 2015 , 10, e0129176	3.7	14
159	Nuclear Localization and Biological Function of Matrix Metalloproteinase-2. <i>FASEB Journal</i> , 2015 , 29, 979.6	0.9	
158	The Activation of Matrix Metalloproteinease-2 by Mitochondrially-Generated Reactive Oxygen/Nitrogen Species. <i>FASEB Journal</i> , 2015 , 29, 955.2	0.9	
157	MMP-2 is localized to the mitochondria-associated membrane of the heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014 , 306, H764-70	5.2	34
156	Smoothelin-B is not a target of matrix metalloproteinase (MMP)-2 in the vasculature of endotoxemic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014 , 92, 887-91	2.4	1
155	Myocardial matrix metalloproteinase-2: inside out and upside down. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 77, 64-72	5.8	63
154	Targeting MMP-2 to treat ischemic heart injury. <i>Basic Research in Cardiology</i> , 2014 , 109, 424	11.8	48

153	Matrix metalloproteinases 2 and 9 as diagnostic tools in Chagas cardiomyopathy. <i>International Journal of Cardiology</i> , 2014 , 177, 46-7	3.2	3
152	Mmp25 facilitates elongation of sensory neurons during zebrafish development. <i>Genesis</i> , 2014 , 52, 833-48	1.9	9
151	Postresuscitation administration of doxycycline preserves cardiac contractile function in hypoxia-reoxygenation injury of newborn piglets*. <i>Critical Care Medicine</i> , 2014 , 42, e260-9	1.4	6
150	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. <i>BMC Cardiovascular Disorders</i> , 2014 , 14, 91	2.3	22
149	Remodeling of aorta extracellular matrix as a result of transient high oxygen exposure in newborn rats: implication for arterial rigidity and hypertension risk. <i>PLoS ONE</i> , 2014 , 9, e92287	3.7	18
148	Matrix metalloproteinase-2 is localized to the mitochondria-associated membrane in the heart (1154.4). <i>FASEB Journal</i> , 2014 , 28, 1154.4	0.9	
147	Matrix metalloproteinase-2 mediate oncostatin-M induced cardiomyocyte dedifferentiation (1151.2). <i>FASEB Journal</i> , 2014 , 28, 1151.2	0.9	
146	Implications of Intracellular Proteolytic Activation of MMP-2 in the Heart 2014 , 335-349		
145	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. <i>Biochemical Pharmacology</i> , 2013 , 86, 469-75	6	9
144	Hydrogen peroxide-induced necrotic cell death in cardiomyocytes is independent of matrix metalloproteinase-2. <i>Toxicology in Vitro</i> , 2013 , 27, 1686-92	3.6	19
143	Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart. <i>Archives of Biochemistry and Biophysics</i> , 2013 , 540, 82-93	4.1	38
142	Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. <i>American Heart Journal</i> , 2013 , 165, 558-66	4.9	37
141	Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass. <i>Critical Care Medicine</i> , 2013 , 41, 2512-20	1.4	22
140	Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism. <i>Journal of Cellular and Molecular Medicine</i> , 2013 , 17, 1588-97	5.6	10
139	Phosphorylation status of 72 kDa MMP-2 determines its structure and activity in response to peroxynitrite. <i>PLoS ONE</i> , 2013 , 8, e71794	3.7	24
138	Intracellular Matrix Remodeling and Cardiac Function in Ischemia/Reperfusion Injury 2013 , 467-485		
137	Doxycycline Attenuates Cardiac Injury and Improves Cardiac Function with Inhibition of Myocardial Matrix Metalloproteinase (MMP)-2 in a Swine Model of Hypoxia- Reoxygenation (H-R). <i>FASEB Journal</i> , 2013 , 27, 1129.9	0.9	
136	Role of MMP-2 activation in oncostatin-M induced cardiomyocyte dedifferentiation. <i>FASEB Journal</i> , 2013 , 27, 1146.4	0.9	

135	Analysis of mitochondrial MMP-2 and MMP-9 in the heart. <i>FASEB Journal</i> , 2013 , 27, 1129-10	0.9	
134	Intracellular proteases and sarcomere disassembly in neonatal cardiomyocytes. <i>FASEB Journal</i> , 2013 , 27, 1217-33	0.9	
133	Nuclear MMP-2: presence and activity in cardiac myocytes. <i>FASEB Journal</i> , 2013 , 27, 995-4	0.9	
132	Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2. <i>FEBS Journal</i> , 2012 , 279, 2444-54	5.7	29
131	Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. <i>Biochemical and Biophysical Research Communications</i> , 2012 , 423, 1-5	3.4	32
130	Mechanisms of cytosolic targeting of matrix metalloproteinase-2. <i>Journal of Cellular Physiology</i> , 2012 , 227, 3397-404	7	57
129	Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 662-8	9.4	35
128	Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemia-reperfusion injury. <i>Heart</i> , 2012 , 98, 656-62	5.1	13
127	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase (MMP)-2. <i>FASEB Journal</i> , 2012 , 26, lb657	0.9	
126	Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. <i>Pharmacological Research</i> , 2011 , 64, 551-60	10.2	66
125	Intracellular MMP-2: Role in Normal and Diseased Hearts 2011 , 17-28		
124	Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. <i>Trends in Cardiovascular Medicine</i> , 2011 , 21, 112-8	6.9	43
123	Smoothelin-B: a potential target of matrix metalloproteinase (MMP)-2 in the vasculature of endotoxemic rats. <i>FASEB Journal</i> , 2011 , 25, 1115-19	0.9	
122	Peroxynitrite-induced changes in 72kDa matrix metalloproteinase-2 activity are further regulated by its phosphorylation status. <i>FASEB Journal</i> , 2011 , 25, 1096-2	0.9	
121	Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. <i>Cardiovascular Research</i> , 2010 , 85, 413-23	9.9	192
120	Cardiac function is not significantly diminished in hearts isolated from young caveolin-1 knockout mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H1183-9	5.2	11
119	Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H45-51	5.2	51
118	Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. <i>Circulation</i> , 2010 , 122, 2039-47	16.7	140

117	Caveolin-1 exists and may function in cardiomyocytes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010 , 88, 73-6	2.4	18
116	Antioxidant treatment protects diabetic rats from cardiac dysfunction by preserving contractile protein targets of oxidative stress. <i>Journal of Nutritional Biochemistry</i> , 2010 , 21, 827-33	6.3	39
115	Activation of MMP-2 as a key event in oxidative stress injury to the heart. <i>Frontiers in Bioscience - Landmark</i> , 2009 , 14, 699-716	2.8	18
114	Plasma matrix metalloproteinases in neonates having surgery for congenital heart disease. <i>Heart International</i> , 2009 , 4, e4	0.3	1
113	Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. <i>Circulation</i> , 2009 , 119, 2480-9	16.7	62
112	Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. <i>Cardiovascular Research</i> , 2009 , 83, 698-706	9.9	31
111	Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. <i>Biochemical Pharmacology</i> , 2009 , 77, 826-34	6	160
110	Post-resuscitation NOS inhibition does not improve hemodynamic recovery of hypoxic newborn pigs. <i>Intensive Care Medicine</i> , 2009 , 35, 1628-35	14.5	1
109	Proteomics analysis of changes in myocardial proteins during endotoxemia. <i>Journal of Proteomics</i> , 2009 , 72, 648-55	3.9	9
108	Inhibition of matrix metalloproteinase-2 by PARP inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 387, 646-50	3.4	39
107	Cleavage of glycogen synthase kinase-3beta by matrix metalloproteinase-2 enhances its kinase activity. <i>FASEB Journal</i> , 2009 , 23, 577.6	0.9	
106	Does caveolin-1 knockout affect matrix metalloproteinase-2 activity and contractile function in the isolated working mouse heart?. <i>FASEB Journal</i> , 2009 , 23, 812.3	0.9	
105	Effect of Multiparity on Vascular Compliance and Collagen Content. <i>FASEB Journal</i> , 2009 , 23, 951.7	0.9	
104	Matrix metalloproteinase-2 co-localizes with titin in cardiac myocytes and contributes to its proteolysis in ischemia-reperfusion injury. <i>FASEB Journal</i> , 2009 , 23, 812.11	0.9	
103	Protective action of doxycycline against diabetic cardiomyopathy in rats. <i>British Journal of Pharmacology</i> , 2008 , 155, 1174-84	8.6	52
102	Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. <i>British Journal of Pharmacology</i> , 2008 , 153, 676-83	8.6	30
101	Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4. <i>FEBS Letters</i> , 2008 , 582, 1135-40.8		42
100	Endothelial dependence of matrix metalloproteinase-mediated vascular hyporeactivity caused by lipopolysaccharide. <i>European Journal of Pharmacology</i> , 2008 , 582, 116-22	5.3	11

99	Calcium extrusion by plasma membrane calcium pump is impaired in caveolin-1 knockout mouse small intestine. <i>European Journal of Pharmacology</i> , 2008 , 591, 80-7	5.3	25
98	Smooth muscle NOS, colocalized with caveolin-1, modulates contraction in mouse small intestine. <i>Journal of Cellular and Molecular Medicine</i> , 2008 , 12, 1404-15	5.6	17
97	Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental <i>Trypanosoma cruzi</i> infection. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1468-76	7	75
96	Role of oxidative stress in multiparity-induced endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H1736-42	5.2	26
95	Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. <i>Basic Research in Cardiology</i> , 2008 , 103, 431-43	11.8	45
94	Calcium extrusion by plasma membrane calcium pump is impaired in absence of intact caveolae. <i>FASEB Journal</i> , 2008 , 22, 916.8	0.9	1
93	Inhibiting matrix metalloproteinase-2 (MMP-2) reduces endothelial damage in isolated rat hearts during ischemia-reperfusion. <i>FASEB Journal</i> , 2008 , 22, 914.1	0.9	
92	Post-translational modification of matrix metalloproteinase-2 by peroxynitrite. <i>FASEB Journal</i> , 2008 , 22, 750.20	0.9	
91	Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. <i>Annual Review of Pharmacology and Toxicology</i> , 2007 , 47, 211-42	17.9	243
90	Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. <i>British Journal of Pharmacology</i> , 2007 , 152, 189-205	8.6	153
89	Matrix metalloproteinase-2, caveolins, focal adhesion kinase and c-Kit in cells of the mouse myocardium. <i>Journal of Cellular and Molecular Medicine</i> , 2007 , 11, 1069-86	5.6	29
88	Isolated heart perfusion according to Langendorff---still viable in the new millennium. <i>Journal of Pharmacological and Toxicological Methods</i> , 2007 , 55, 113-26	1.7	228
87	Nitric oxide, peroxynitrite and matrix metalloproteinases: Insight into the pathogenesis of sepsis. <i>Advances in Experimental Biology</i> , 2007 , 367-396		
86	PPARalpha: essential component to prevent myocardial oxidative stress?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H11-2	5.2	2
85	Hydrogen peroxide causes cardiac dysfunction independent from its effects on matrix metalloproteinase-2 activation. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007 , 85, 341-8	2.4	8
84	Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. <i>FASEB Journal</i> , 2007 , 21, 2486-95	0.9	120
83	Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 42, 896-901	5.8	63
82	Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 43, 429-36	5.8	123

81	Differential inhibitory control of circular and longitudinal smooth muscle layers of Balb/C mouse small intestine. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2007 , 131, 36-44	2.4	10
80	Smooth muscle nitric oxide synthase, co-localized with caveolin-1, modulates contraction in mouse small intestine. <i>FASEB Journal</i> , 2007 , 21, A808	0.9	
79	The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver. <i>Current Pharmaceutical Design</i> , 2006 , 12, 2923-34	3.3	39
78	Impact of caveolin-1 knockout on NANC relaxation in circular muscles of the mouse small intestine compared with longitudinal muscles. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G394-403	5.1	11
77	Caveolin-1 knockout alters beta-adrenoceptors function in mouse small intestine. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 291, G1020-30	5.1	11
76	Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 316, 154-61	4.7	89
75	Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction. <i>British Journal of Pharmacology</i> , 2006 , 149, 31-42	8.6	40
74	Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. <i>European Heart Journal</i> , 2005 , 26, 27-35	9.5	103
73	The involvement of superoxide and iNOS-derived NO in cardiac dysfunction induced by pro-inflammatory cytokines. <i>Journal of Molecular and Cellular Cardiology</i> , 2005 , 39, 833-40	5.8	50
72	Nitrosative stress and pharmacological modulation of heart failure. <i>Trends in Pharmacological Sciences</i> , 2005 , 26, 302-10	13.2	193
71	Turmoil in the Cardiac Myocyte: Acute Intracellular Activation of Matrix Metalloproteinases 2005 , 213-237		
70	Inhibition of endogenous nitric oxide in the heart enhances matrix metalloproteinase-2 release. <i>British Journal of Pharmacology</i> , 2005 , 145, 43-9	8.6	24
69	Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. <i>Circulation</i> , 2005 , 112, 544-52	16.7	232
68	MMP-2 and MMP-9 and their tissue inhibitors in the plasma of preterm and term neonates. <i>Pediatric Research</i> , 2004 , 55, 794-801	3.2	53
67	Pyruvate prevents cardiac dysfunction and AMP-activated protein kinase activation by hydrogen peroxide in isolated rat hearts. <i>Canadian Journal of Physiology and Pharmacology</i> , 2004 , 82, 409-16	2.4	21
66	Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. <i>FASEB Journal</i> , 2004 , 18, 1943-5	0.9	44
65	Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. <i>FASEB Journal</i> , 2004 , 18, 690-2	0.9	201
64	Inhibition of inducible nitric oxide synthase and superoxide production reduces matrix metalloproteinase-9 activity and restores coronary vasomotor function in rat cardiac allografts. <i>European Journal of Cardio-thoracic Surgery</i> , 2004 , 26, 262-9	3	22

63	Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. <i>Critical Care Medicine</i> , 2004 , 32, 1332-7	1.4	32
62	Peroxynitrite in Myocardial Ischemia-Reperfusion Injury 2004 , 201-211		1
61	Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. <i>Cardiovascular Research</i> , 2003 , 57, 426-33	9.9	106
60	Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: A potential role for MMP-9. <i>Molecular and Cellular Biochemistry</i> , 2003 , 251, 61-66	4.2	37
59	Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. <i>British Journal of Pharmacology</i> , 2003 , 138, 532-43	8.6	331
58	Inhaled nitric oxide inhibits the release of matrix metalloproteinase-2, but not platelet activation, during extracorporeal membrane oxygenation in adult rabbits. <i>Journal of Pediatric Surgery</i> , 2003 , 38, 534-8	2.6	6
57	Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoectardial] ischemia-reperfusion injury. <i>Circulation</i> , 2003 , 107, 2487-92	16.7	101
56	Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: A potential role for MMP-9 2003 , 61-66		1
55	Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. <i>Molecular and Cellular Biochemistry</i> , 2003 , 251, 61-6	4.2	14
54	Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. <i>Cardiovascular Research</i> , 2002 , 53, 165-74	9.9	150
53	Peroxynitrite in myocardial ischemia-reperfusion injury. <i>Heart Failure Reviews</i> , 2002 , 7, 359-69	5	33
52	Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. <i>Circulation</i> , 2002 , 106, 1543-9	16.7	372
51	Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. <i>Circulation Research</i> , 2002 , 90, 100-6	15.7	152
50	Nitrate tolerance does not increase production of peroxynitrite in the heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 283, H69-76	5.2	22
49	Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 283, H1108-15	5.2	108
48	Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 296, 937-41	3.4	52
47	Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. <i>Journal of Clinical Investigation</i> , 2002 , 109, 735-743	15.9	206
46	Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. <i>Journal of Clinical Investigation</i> , 2002 , 109, 735-43	15.9	96

45	Peroxynitrite: toxic or protective in the heart?. <i>Circulation Research</i> , 2001 , 88, E12-3	15.7	25
44	Inhibition of peroxynitrite-induced dityrosine formation with oxidized and reduced thiols, nitric oxide donors, and purine derivatives. <i>Antioxidants and Redox Signaling</i> , 2001 , 3, 165-71	8.4	11
43	Roles of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury and ischemic preconditioning 2001 , 191-206		2
42	The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. <i>Critical Care Medicine</i> , 2000 , 28, 2584-90	1.4	116
41	Influence of beta-adrenoceptor tone on the cardioprotective efficacy of adenosine A(1) receptor activation in isolated working rat hearts. <i>British Journal of Pharmacology</i> , 2000 , 131, 537-45	8.6	1
40	Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. <i>Circulation Research</i> , 2000 , 87, 241-7	15.7	377
39	The hemodynamic effects of inhaled nitric oxide and endogenous nitric oxide synthesis blockade in newborn piglets during infusion of heat-killed group B streptococci. <i>Critical Care Medicine</i> , 2000 , 28, 800-8	1.4	23
38	Upregulation of neuronal nitric oxide synthase in skeletal muscle by swim training. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000 , 279, H1757-66	5.2	36
37	Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. <i>Circulation</i> , 2000 , 101, 1833-9	16.7	378
36	Glutathione protects against myocardial ischemia-reperfusion injury by detoxifying peroxynitrite. <i>Journal of Molecular and Cellular Cardiology</i> , 2000 , 32, 1669-78	5.8	52
35	Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999 , 276, R265-76	3.2	92
34	Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999 , 276, H1861-7	5.2	27
33	Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. <i>Circulation</i> , 1999 , 100, 2260-6	16.7	112
32	Response of fetal rabbit ductus arteriosus to bradykinin: role of nitric oxide, prostaglandins, and bradykinin receptors. <i>Pediatric Research</i> , 1999 , 45, 568-74	3.2	13
31	K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation. <i>British Journal of Pharmacology</i> , 1998 , 124, 639-46	8.6	8
30	Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates. <i>Lancet, The</i> , 1998 , 351, 1181-2	40	70
29	Thiols protect the inhibition of myocardial aconitase by peroxynitrite. <i>Archives of Biochemistry and Biophysics</i> , 1998 , 350, 104-8	4.1	50
28	Intrinsic ANG II type 1 receptor stimulation contributes to recovery of postischemic mechanical function. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998 , 274, H1524-31	5.2	4

27	Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998 , 275, H1971-8	5.2	11
26	Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998 , 275, H1016-23	5.2	23
25	Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. <i>Cardiovascular Research</i> , 1997 , 33, 422-32	9.9	255
24	Peroxynitrite impairs cardiac contractile function by decreasing cardiac efficiency. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1997 , 272, H1212-9	5.2	45
23	Nitric oxide and platelet function: implications for neonatology. <i>Seminars in Perinatology</i> , 1997 , 21, 409-17	3.7	62
22	Rapid increase in inducible nitric oxide synthase gene expression in the heart during endotoxemia. <i>European Journal of Pharmacology</i> , 1996 , 303, 141-4	5.3	22
21	Characterization of 5AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. <i>Lipids and Lipid Metabolism</i> , 1996 , 1301, 67-75		204
20	Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. <i>Circulation Research</i> , 1996 , 79, 940-8	15.7	156
19	Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. <i>Cardiovascular Research</i> , 1995 , 30, 432-439	9.9	5
18	The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. <i>British Journal of Pharmacology</i> , 1995 , 114, 27-34	8.6	176
17	Role of NO in vascular smooth muscle and cardiac muscle function. <i>Trends in Pharmacological Sciences</i> , 1994 , 15, 255-9	13.2	80
16	Human pancreatic islet beta-cell destruction by cytokines is independent of nitric oxide production. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 79, 1058-1062	5.6	70
15	Porcine ventricular endocardial cells in culture express the inducible form of nitric oxide synthase. <i>British Journal of Pharmacology</i> , 1993 , 108, 1107-10	8.6	44
14	Production of 15-HETE by cultured smooth muscle cells from cerebral artery. <i>Pharmacology</i> , 1993 , 46, 211-23	2.3	9
13	Analysis of myocardial plasmalogen and diacyl phospholipids and their arachidonic acid content using high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 1993 , 213, 140-6	3.1	9
12	Lysoplasmylethanolamine accumulation in ischemic/reperfused isolated fatty acid-perfused hearts. <i>Circulation Research</i> , 1992 , 70, 1161-8	15.7	23
11	Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. <i>British Journal of Pharmacology</i> , 1992 , 105, 575-80	8.6	499
10	The l-Arginine. <i>Journal of Cardiovascular Pharmacology</i> , 1991 , 17, S1-S9	3.1	69

9	Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 2166-70	11.5	431
8	Nitric oxide synthase in cultured endocardial cells of the pig. <i>British Journal of Pharmacology</i> , 1991 , 104, 21-4	8.6	122
7	Cerebral arteries can generate 5- and 15-hydroxyeicosatetraenoic acid from arachidonic acid. <i>Canadian Journal of Physiology and Pharmacology</i> , 1990 , 68, 807-13	2.4	15
6	Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. <i>British Journal of Pharmacology</i> , 1990 , 101, 746-52	8.6	1516
5	Effects of Vasospasm on Levels of Prostacyclin and Thromboxane A2 in Cerebral Arteries of the Monkey. <i>Neurosurgery</i> , 1988 , 22, 45-50	3.2	43
4	Mechanisms of arachidonic acid-induced contractions of canine cerebral arteries. <i>European Journal of Pharmacology</i> , 1987 , 136, 345-52	5.3	19
3	Release of leukotrienes into the perfusate of calcium-ionophore stimulated rabbit lungs. Influence of 5-lipoxygenase inhibitors. <i>Biochemical Pharmacology</i> , 1986 , 35, 183-93	6	45
2	An efficient and highly flexible synthesis of (E)-unsaturated Eoxoesters. <i>Tetrahedron Letters</i> , 1982 , 23, 2013-2016	2	9
1	Matrix metalloproteinase-2 mediates ribosomal RNA transcription by cleaving nucleolar histones		1